ZORYVE (roflumilast) cream 0.3%

ZORYVE is a next-generation PDE4i for plaque psoriasis.

ZORYVE brings meaningful innovation to the treatment of plaque psoriasis by simplifying disease management.1–3


ZORYVE cream is indicated for topical treatment of plaque psoriasis, including intertriginous areas, in patients 6 years of age and older.

Important Safety Information

ZORYVE is contraindicated in patients with moderate to severe liver impairment (Child-Pugh B or C). 

The most common adverse reactions (≥1%) include diarrhea (3.1%), headache (2.4%), insomnia (1.4%), nausea (1.2%), application site pain (1.0%), upper respiratory tract infection (1.0%), and urinary tract infection (1.0%). 

Please see the full Prescribing Information for ZORYVE below.

For more information,
visit the ZORYVE website.

Arcutis is dedicated to affordable access to therapy.

Our commitment to solving today’s biggest medical dermatology challenges doesn’t stop at bringing new treatment options. There’s more to our Arcutis DNA. It’s why we believe in responsible pricing and helping patients get access to our product through ZORYVE Direct and our commercial co-pay program, the ZORYVE Direct Savings Program, as well as Arcutis Cares. 

ZORYVE Direct provides prescription status updates, refill reminders, and information to help patients stay on track with ZORYVE as prescribed by their healthcare provider. It also helps with out-of-pocket costs for eligible patients with commercial drug insurance.

The Arcutis Cares patient assistance program (PAP) provides ZORYVE at no cost to eligible uninsured or underinsured patients with financial need.

Subject to eligibility criteria and maximum program limitation. This offer is not valid for patients without commercial drug insurance or whose prescription claims are eligible to be reimbursed, in whole or in part, by any government program. Please see Terms and Conditions.

Subject to financial eligibility requirements. Other terms and restrictions apply.


  1. ZORYVE®. Prescribing information. Arcutis Biotherapeutics, Inc; 2023. 
  2. Dong C, Virtucio C, Zemska O, et al. Treatment of skin inflammation with benzoxaborole phosphodiesterase inhibitors: selectivity, cellular activity, and effect on cytokines associated with skin inflammation and skin architecture changes. J Pharmacol Exp Ther. 2016;358(3):413-422. 
  3. Data on File. Arcutis Biotherapeutics, Inc.

PDE4i = phosphodiesterase-4 inhibitor

CRP-ARQ-151-220004 v3.0 10/23

Meaningful innovation at a glance.

Download our corporate fact sheet.